澳利达集团简介
2012-01-04 13:59:34   来源:   评论:0 点击:

澳利达(ALD)医药集团简介 澳利达医药集团创建于1985年,现已发展成为集科研能力、生产能力、营销能力于一体的大型医药企业集团,拥有成员企业28家,资产13亿元人民币,员工2180人,年实现销售收入13....
 澳利达(ALD)医药集团简介

    澳利达医药集团创建于1985年,现已发展成为集科研能力、生产能力、营销能力于一体的大型医药企业集团,拥有成员企业28家,资产13亿元人民币,员工2180人,年实现销售收入13.5亿元人民币,利税9500万元人民币。2000年全国流通百强企业排名第十七位,各项主要经营指标均居全国同行业领先地位。企业荣获全国五一劳动奖状、黑龙江省文明标兵、黑龙江省高新技术企业等殊荣,被黑龙江省人民政府确定为北药开发重点培植企业。董事长周有财先生拥有药学博士学位、北京大学EMBA学位,享受国务院特殊津贴,曾先后获得国家科研基金、专利成果10余项,荣获全国劳动模范、全国五一劳动奖章荣誉称号,九届、十届、十一届全国人大代表,黑龙江省工商联副主席。
    澳利达奈德制药有限公司(ALD NED)为集团的核心生产企业。公司由德国保尔工程公司和中国天辰化学公司按照国际标准进行设计,厂区三面农田环绕,空气清新,无污染源,占地面积10万平方米,建筑面积3.5万平方米,内部规划新颖独特,结构科学合理,是目前亚洲地区规模较大、标准较高的新型制药企业。公司现有软胶囊剂、缓释微丸剂、冻干粉针剂、水针剂、颗粒剂、片剂、硬胶囊剂、丸剂和口服液剂及化学合成车间。正在筹建喷雾剂、软膏剂和发酵合成车间。发酵合成车间主要以发酵法生产L-谷氨酰胺,用于施林(复方L-谷氨酰胺)的生产,以上二个剂型和一个车间的工艺布局已在设计中。公司主要有奥迈必利缓释微丸、奥地迈尔缓释微丸、施林、奥力保克、考夫克、牛黄清感胶囊等近百个产品,获得国家发明专利和国内独家生产的品种9个。缓释微丸技术已成为公司的主导技术,该技术具有给药次数少,毒副作用小,保持平稳而有效血药浓度的优势,克服了普通药物普遍存在的峰谷现象,最大限度的发挥了疗效。以此技术生产研制的系列缓释微丸产品均为国内首创,属填补国内空白品种。公司年生产软胶囊5亿粒、缓释微丸胶囊3亿粒、冻干粉针2亿支、水针1.5亿支、颗粒剂10亿袋、片剂10亿片、硬胶囊10亿粒。公司生产、检验设备先进,其中,FL-120沸腾干燥制粒机、DPH-200包装联动生产线等主要生产设备均达到国际先进水平。
    澳利达哈尔滨药物研究所承担着集团的药品研发工作。科研力量雄厚,研发人员中现有博士学位7人,硕士学位12人,主任药师7人。检验设备精密、先进。几年来,相继开发上市了复方谷氨酰胺颗粒、奥迈必利缓释微丸、牛黄清感胶囊等近30多个品种。其中别嘌醇缓释微丸获得黑龙江省科技进步一等奖,复方谷氨酰胺颗粒获得黑龙江省医药行业协会科技进步一等奖,牛黄清感胶囊获得国家药物组方发明专利。缓释微丸项目被国家发改委列为高新技术产业发展专项。近年来,药物研究所的主要研究方向一是中药现代化的研究,二是开发缓释微丸技术,三是五味子产业化的研究,并均取得了理想的经济效益和社会效益。
    澳利达药业股份有限公司作为集团的核心企业之一,承担着集团产品的营销工作,公司在北京和上海设有两个事业部,在沈阳、天津、成都、重庆、广州、西安等21个大中城市设有销售服务机构,业务网点遍及国内31个省、区、市,与此同时与日本第一制药、法国爱的发制药建立了长期稳固的业务关系。
    集团控股公司天一药房与美信医药国际连锁机构联合,引用国际医药管理技术及理念,建立辐射全国的医药连锁网络,推进整合行销和多品牌营销等全新营销模式,经营“健康+专业+便利”理念的药房,预计2011年国内连锁门店总量达到1000家,为顾客提供个性化照顾和高品质服务,缔造最优秀的专业药房。构建营销网、物流网、信息网有机整合的国内医药零售连锁网络体系。
    集团药品物流中心和生物制药与生物保健品生产基地位于哈尔滨市机场路,占地30000平方米,投资1.5亿元。物流中心负责集团生产和经营药品的全国配送业务,生物基地主要生产生物信息素、生物保健品。面向未来,集团恪守“精制良药,造福人群”的经营理念,立足国内,放眼世界,以科学严谨、追求创新的态度和精神,使集团发展成为具有竞争力和蓬勃发展的国际化集团企业。
 
Introduction to Heilongjiang Aolida Medical Group
 
The Heilongjiang Aolida Medical Group (“ALD Group”), founded in 1985, has expended into a multi-industrial company through the past 23 years. It is now a leading pharmaceutical enterprise operating product developing, manufacturing and marketing in diversified pharmaceutical products. ALD Group possesses a total capital of 1.3 billion RMB inclusive of 28 subsidiaries. With more than 2,180 employees’ diligent work, ALD Group successfully realized a business income of 1.35 billion RMB and tax revenue of 95 million RMB last year.
 
ALD Group ranked 17th of the top 100 state circulation enterprises in 2000 and it now also leads the pharmaceutical industry of varied major indices. ALD Group has won many national and province wide awards such as National Labor Award and Cultural Pivot of Heilongjiang Provence. It is also recognized as High-New Technology Enterprise of Heilongjiang. ALD Group has been determined as the key cultivation enterprise of the North medicine development by the government of Heilongjiang Province.
 
Mr. Zhou Youcai, the chairman of ALD Group, is a PhD in pharmaceutics and also holds EMBA degree from Peking University. Mr. Zhou enjoys the special allowance from the national council and has obtained the national scientific research fund and more than 10 patent achievements, he had the honor to receive the national labor model, and the ninth, tenth, eleventh NPC, and he is the vice chairman of federations of industry in Heilongjiang province.
 
Heilongjiang Aolida Ned Pharmaceutical Co. Ltd. (“ALD NED”) is the core production of ALD Group. The company carries on the design by the German Paul Engineering and the Chinese Tian Chen chemistry company according to the international standard. The factory of ALD NED covers 100,000 square meters with 35,000 square meters floor space and is surrounded by farmland on three sides. It has a modern interior design with unique and sound layout. ALD NED is a pharmaceutical enterprise with large scale and high standard in Asian area.
 
 ALD NED has nine cGMP facilities, mainly manufacturing nine formulations: soft capsules, slow-release nano-pills (sustained-release pellets), freeze-dry powder syringes, liquid syringes, particles, tablets, hard capsules, pills, and oral liquid. The workshop for spray solution, soft medicinal extract and fermentation synthesizes is being prepared to construct. Fermentation synthetic workshop is to synthesize L – glutamine which is produced mainly by fermentation. L-Glutamine is a necessary to produce Shilin. The layout of above mentioned workshop is being designed.
 
By now, ADL Group has Aomaibili sustained-release pellets, Aodimaer sustained-release pellets, Shilin, Aolibaoke, Kaofuke, Niuhuang Flu Pills, nearly hundred kinds of products. Among those products, nine of them obtained the patent of Chinese invention and exclusive production rights in China. The technology of sustained-release pellets has already been the leading technology within the company. The advantage of the sustained-release pellets is that it need less dosing, has fewer side effects and could maintain the drug concentration smoothly and effectively. The sustained-release pellet has overcome the volatility in ordinary medicine to reduce the stimulation of gastro-intestinal tract. It is a cutting-edge technology first appears and fills the gap of sustained-release pellet in China.
 
ADL Group is capable to produce a total of 500 million of capsules, 300 million of slow-release nano-pills, 200 million of freeze-dry powder syringes, 150 million bottles of liquid syringes, 1 billion bags of particles, 1 billion of pills and 1.5 billion bottles of oral liquid in each year. It has the advanced production line and examination facilities. The major production line such as FL-120 ebullition dry pelletizer and the DPH-200 packing production lines have reached the advanced international level.
 
Harbin Aolida pharmaceutical institute is undertaking the research and development work of ALD Group. It has strong capability of conducting scientific research. The research team includes 7 doctors, 12 masters and 7 professors of pharmacy. The institute also has advanced examination facilities such as liquid phase chromatograph, gas phase chromatograph, infrared spectrophotometer and visual purple spectrophotometer which are all introduced from overseas.
 
ALD Group has developed L – glutamine, Aomaibili sustained-release pellets and Niuhuang Flu Pills nearly 30 kinds of production in the past several years. The Aomaibili sustained-release pellets has won the first prize of the advance technology in Heilongjiang Province, L – glutamine has won the first prize of medicine profession association advance technology in Heilongjiang province and Niuhuang Flu Pills has won the patent of national medicine group of invention. The project of slow-release nano-pills is recognized as the special project of new and high technology by national Development and Planning Commission.
 
In recent years, Aolida Pharmaceutical institute has focused research on three major areas: 1. modernization of traditional Chinese medicine; 2. development of the technology of slow-release nano-pills; 3. the sub-industrial production research of the fruit of Chinese magnolia vine. The results of research returned ALD Group favorable economic efficiency and the social efficiency.
 
As the one of the Core enterprises, Aolida pharmaceutical industry Limited liability company which undertakes the marketing activities of ALD Group. The company has two sales divisions located in Beijing and Shanghai and also operates sales departments within 21 cities, such as Shenyang, Tianjin, Chengdu, Chongqing, Guangzhou, Xi'an etc. It services 31 provinces and cities. At the same time pharmaceutical limited has established a long-term stable business relation with the first drugs manufacture of Japan and Ethypharm of France.
 
ALD Group introduces the advanced management and company principles by alliance of controlled subsidiary Tianyi pharmacy and Meixin international chain store. It established the sales network which radiates to the whole country. By integrated its marketing and set multi-brand strategy, ALD Group promotes a new marketing model which advocates “health + professional + convenience”. As a result of building sales and logistic network and providing finest service in addition to specialized pharmacy, number of the chain stores is estimated to reach 1,000 by year 2011.
 
The logistic center sits together with biopharmaceutical and health care product manufacturing base in Haerbin Airport Road. It total investment is 150 million RMB and covers a total of 30,000 square meters. The logistic center is responsible to distribute all drugs produced and operated by ALD Group to the whole country. The manufacturing base is to produce the biology information element, and the biological healthy product.
 
Aiming to the future, ALD Group will follow the enterprise spirit of “Improves the medicine quality unceasingly, and benefits the humanity”. With the attitude towards preciseness and spirit of pursuing innovation, ALD Group is developing its competitiveness and striving not only to be the top in pharmaceutical industry in China but also to take a part in the global market.
 
 

相关热词搜索:澳利达 澳立达 集团

上一篇:第一页
下一篇:企业荣誉

分享到: 收藏
频道本月排行